Silexion cuts warrant price to raise $840K in cash infusion
What's the deal? Silexion TherapeuticsDealroom has a profile for this one. Try Dealroom → has agreed to raise roughly $840,000 by inducing holders of its series E warrants to exercise them early at a discounted price. The company disclosed the inducement offer letter, dated September 28, 2026, in a Form 8-K filed the following day.
The mechanics: Holders of 3,216,928 series E warrants consented to exercise at $0.2603 per share, down from the original $0.65. In return, Silexion will issue 6,433,856 new warrants — split evenly between series F and series G — each priced at $0.2603.
Why now? The series E warrants were issued during Silexion's August 11, 2026 public offering with a five-year term. Cutting the price by 60% offers holders an incentive to convert now, delivering the company an early cash injection.
H.C. Wainwright & Co.Dealroom has a profile for this one. Try Dealroom → is acting as exclusive placement agent, earning a 7.0% cash fee plus a 1.0% management fee on gross proceeds. It will also receive warrants to buy up to 225,185 ordinary shares at $0.3254 each.
What's the money for? Net proceeds are earmarked for general corporate purposes. Silexion agreed to file a resale registration statement on Form S-3 within 30 days and to avoid new share issuances for 15 days after closing, plus variable rate transactions for a year.
The signal: At $840,000, the raise sits at the very bottom of the funding scale — a small, dilutive lever pulled to keep cash flowing rather than a growth round. For a microcap biotech, repricing warrants is a fast route to capital, but it signals limited alternatives.
Read more: kalkinemedia.com
Image credit: Generated with Gemini
